News
RM plc: Notification of Full Year Results
RM plc: Extension and amendment of Banking facility
RM plc: Holding(s) in Company
RM plc: Holding(s) in Company
RM plc: Full Year Trading Update
RM plc: Bank covenants waiver agreement
RM plc: Strategy timetable and closure of the Consortium business
RM plc: Holding(s) in Company
RM plc: Holding(s) in Company
RM plc: Sale of IPv4 addresses
Why Plug Power, Bloom Energy, and Nikola All Dropped Like a Rock Today
Hydrogen-related stocks had a rough day on Monday as downgrades and higher interest rates hit many energy-related stocks. As the cost of financing goes higher, it makes it harder to finance projects
RM plc: Holding(s) in Company
The SEC's Warning to Plug Power Looks Like a Bad Omen for Investors
Hydrogen company Plug Power (NASDAQ: PLUG) recently settled a multi-year investigation by the SEC, but the regulator still has ongoing concerns. In this video, Motley Fool contributors Jason Hall
RM plc: Director/PDMR Performance Share Plan Awards
RM plc: Successful negotiation of bank covenants waiver for August 2023
RM plc: Holding(s) in Company
RM plc: Holding(s) in Company
RM plc: Share Dealing Notification
RM plc: Interim Results for the six months ended 31 May 2023
RM plc: Holding(s) in Company
Why Shares of Plug Power, FuelCell Energy, and Ballard Power Systems Are Charging Higher This Week
Hydrogen related stocks are having a week. Shares of Plug Power (NASDAQ: PLUG) are powering higher as are FuelCell Energy (NASDAQ: FCEL) and Ballard Power Systems (NASDAQ: BLDP) for a variety of
RM plc: Non-Executive Board changes
RM plc: Notification of Half Year Results
What Is the Best Hydrogen Stock?
Hydrogen stocks have grown a lot in recent years, but they're having a problem turning revenue growth into profits. In this video, Travis Hoium covers the industry's growth, its margin challenges
Why uniQure Stock Is Crashing Today
Shares of uniQure NV (NASDAQ: QURE) are plummeting today, down by 40% as of 11:09 a.m. ET. The steep decline came after the company announced interim results from a phase 1/2 clinical study